SIM
URGN icon

Spark Investment Management’s UroGen Pharma URGN Stock Holding History

Spark Investment Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-70,700
Closed -$2.63M – 730
2017
Q4 		$2.63M Buy
70,700
+33,600
+91% +$1.2M 0.14% 218
2017
Q3 		$1.17M Sell
37,100
-10,300
-22% -$227K 0.06% 358
2017
Q2 		$856K Buy
+47,400
New +$823K 0.05% 417

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Spark Investment Management's URGN Position: Q1 2018 in Review

Spark Investment Management sold out of UroGen Pharma (URGN) in Q1 2018, closing a stake of 70,700 shares — an estimated $2.63M sold.

Spark Investment Management first reported a position in URGN in Q2 2017 and held it in 3 quarters. The position peaked at $2.63M in Q4 2017. 43 funds tracked by Wall St. Rank hold URGN as of Q1 2018.

  • Spark Investment Management reported no remaining UroGen Pharma position as of Q1 2018 after selling out during the quarter.
  • Spark Investment Management sold 70,700 UroGen Pharma shares in Q1 2018, an estimated $2.63M.
  • Spark Investment Management first reported a position in UroGen Pharma in Q2 2017 and held it in 3 quarters.
  • Spark Investment Management's UroGen Pharma position peaked at $2.63M in Q4 2017.
  • 43 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2018.

Based on Spark Investment Management's 13F filing for Q1 2018, filed 10 May 2018.